Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar 30;30(7):709-17.
doi: 10.1002/sim.4131. Epub 2010 Nov 30.

A method to estimate treatment efficacy among latent subgroups of a randomized clinical trial

Lily L Altstein  1 , Gang Li, Robert M Elashoff
Affiliations

A method to estimate treatment efficacy among latent subgroups of a randomized clinical trial

Lily L Altstein et al. Stat Med. .

Abstract

Subgroup analysis arises in clinical trials research when we wish to estimate a treatment effect on a specific subgroup of the population distinguished by baseline characteristics. Many trial designs induce latent subgroups such that subgroup membership is observable in one arm of the trial and unidentified in the other. This occurs, for example, in oncology trials when a biopsy or dissection is performed only on subjects randomized to active treatment. We discuss a general framework to estimate a biological treatment effect on the latent subgroup of interest when the survival outcome is right-censored and can be appropriately modelled as a parametric function of covariate effects. Our framework builds on the application of instrumental variables methods to all-or-none treatment noncompliance. We derive a computational method to estimate model parameters via the EM algorithm and provide guidance on its implementation in standard software packages. The research is illustrated through an analysis of a seminal melanoma trial that proposed a new standard of care for the disease and involved a biopsy that is available only on patients in the treatment arm.

PubMed Disclaimer

References

    1. Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE, Roses DF, Karakousis CP, Mozzillo N, Reingten D, Wang H, Glass EC, Cochran AJ The Multicenter Selective Lymphadenectomy Trial Group. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Annals of Surgery. 1999;230(4):453–463. - PMC - PubMed
    1. Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Wang H The Multicenter Selective Lymphadenectomy Trial Group. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Annals of Surgery. 2005;242(3):302–313. - PMC - PubMed
    1. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. Journal of the American Statistical Association. 1996;91(434):444–455.
    1. Imbens GW, Rubin DB. Bayesian inference for causal effects in randomized experiments with noncompliance. Annals of Statistics. 1997;25(1):305–327.
    1. Sommer A, Zeger SL. On estimating efficacy from clinical trials. Statistics in Medicine. 1991;10(1):45–52. - PubMed

Publication types

LinkOut - more resources